Agnete Brunsvik Fredriksen
Chief Scientific Officer Nykode Therapeutics
Agnete Fredriksen, PhD is EVP, Chief Scientific Officer & Business Development at Nykode Therapeutics and a co-founder of the company. She leads the company’s research portfolio, business development activities, and strategic partnerships, while advancing Nykode’s antigen-specific immune tolerance platform and oncology pipeline. As a member of the executive leadership team, she is responsible for corporate development, business development and additional external engagement.
Seminars
Thursday 3rd December 2026
From Promise to Practice: Enabling the Next Generation of Personalized Cancer Vaccines
9:00 am
- Exploring key learnings from clinical and translational development of individualized cancer vaccines
- Leveraging targeted antigen delivery to professional APCs to generate potent, broad, and long-lasting immune responses
- Addressing manufacturing complexity, scalability, and cost to make personalized immunotherapies a sustainable commercial reality
Thursday 3rd December 2026
Fireside Chat: Comparing Personalized vs. Off-the-Shelf Cancer Vaccines to Choose the Right Strategy for the Right Indication
11:30 am
- Which indications are best suited to personalized cancer vaccines and how can they provide clinical advantage?
- What are the key trade-offs between clinical outcomes, manufacturing scalability, speed to patients, and development costs?
- What will determine the long-term commercial success and patient accessibility of personalized versus off-the-shelf cancer vaccines?
